Filtration is used in pharmaceutical industry to purify and separate the component of therapeutic application. Additionally, the process can be used to maintain sterile conditions of processing and prevent contamination of the therapeutic entities. Various methods of filtration like air filtration, water filtration, chemical filtrations, grade filtration are being used for filtration in the pharmaceutical industry. Factors such as growing biotechnology and pharmaceutical sector and rising healthcare expenditure are the major dricvers fort the market growth during the forecast period. The U.S. is the largest market for biopharmaceuticals and accounts for one third of the global market. Moreover, it is estimated that the U.S. biopharmaceutical sector accounts for around 17% of all domestic R&D funded by the U.S. businesses and added an estimated USD 1.2 trillion in economic output of 2014. Additionally, rising global burden of the diseases and increasing demands for healthcare services boosts the market. However, huge capital cost for setting up new production facilities followed by stringent government regulations are estimated to restrain the market growth during the forecast period.
Get a sample report at https://www.marketresearchfuture.com/sample_request/2432 .
The Global Pharmaceutical Filtration Devices Market is growing with the sound pace. According to a recent study report published by the Market Research Future, the Global Pharmaceutical Filtration Devices Market is booming and expected to gain prominence over the forecast period growing. The market is forecasted to demonstrate a sound growth by 2022, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period (2017 – 2022)
Global Pharmaceutical Filtration Devices Market – Competitive Analysis
GE Healthcare (U.S.), Pall Corporation (U.S.), Parker Hannifin Corporation (U.S.), Sartorius Stedim Biotech S.A. (France), Merck KGaA (Germany), Alfa Laval (Sweden), Graver Technologies, LLC (U.S.), Koch Membrane Systems Inc. (U.S.), and GEA Group (Germany) and others are some of the prominent players at the forefront of competition in the Global Pharmaceutical Filtration Devices Market and are profiled in MRFR Analysis.
Characterized by the presence of several well-established and small players, the Global Pharmaceutical Filtration Devices Market appears to be highly competitive and fragmented. International players who are increasingly expanding their footprint in the developing economy, making it difficult for regional vendors to compete with them, especially in terms of features such as product differentiation, product portfolios, quality, and pricing. The market is witnessing intensified competition which is expected to get more intensified further during the forecast period. The intense competition prevalent in the market dictates the consolidation among marketers.
Well established players incorporate acquisition, collaboration, partnership, expansion, and product launch in order to gain competitive advantage in this market and to maintain their market position.
In September, 2016- GE Healthcare acquired Biosafe Group and introduced Sefia, a state-of-the-art, multi-function platform which uses a combination of continuous-flow centrifugation, temperature control and fluidic management to enable purification, concentration, washing and final formulation during cell processing. Combined with GE Healthcare’s existing portfolio, Sefia further advances access to a single-solution manufacturing platform to enable turnkey, scalable manufacturing of cell therapies.
In May, 2015- Danaher Corporation announced today that the company entered into a definitive merger agreement with Pall Corporation pursuant to which Danaher acquired all of the outstanding shares of Pall for USD 127.20 per share in cash, i.e., for a total enterprise value of approximately USD 13.8 billion, including assumed debt and net of acquired cash.
Browse Complete Report at https://www.marketresearchfuture.com/reports/pharmaceutical-filtration-devices-market-2432 .
In February, 2017- Parker Hannifin Corporation, completed the acquisition of CLARCOR Inc., a major manufacturer of filtration products, for approximately USD 4.3 billion in cash which included the assumption of net debt. The strategic transaction created a combined organization with a comprehensive portfolio of filtration products and technologies, offering customers a single streamlined source for all their purification and separation needs.
In April, 2017- Sartorius Stedim Biotech acquired the Umetrics business (from the U.S. based MKS Instruments Group. Umetrics is a highly specialized, globally leading provider of data analytics software for modelling and optimizing development and manufacturing processes. SSB has been a cooperation partner of Umetrics since the end of 2012, distributing and co-marketing their software to major players in the biopharmaceutical industry.
Global Pharmaceutical Filtration Devices Market – Regional Analysis
The Americas holds the largest market share owing to a well-developed pharmaceutical sector and increasing healthcare expenditure. Following the similar trends Europe stands second in the global market. On regional basis Europe is divided into Western Europe and Eastern Europe. Western Europe leads the market due to the presence of the developed economies like Germany, Italy, France, and others. Asia Pacific, is the fastest growing region in the market. On the other hand, the Middle East & Africa holds the least market share, mainly due to the presence of low income countries within the African region.
Company Name: Market Research Future
Contact Person: Akash Anand
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune –